Skip to Content
Søg Menu

Elderly Patients with Mantle Cell Lymphoma Need to be More Intensively Treated

The future for patients with mantle cell lymphoma is to be treated with novel targeted drugs upfront and also immunotherapy. This also includes elderly patients, who have a much worse prognosis, says professor Ingrid Glimelius, Uppsala University, in this MEDtalk from EHA 2024.
Ingrid Glimelius

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Alexander Fuglkjær

Machine learning kan reducere unødvendige indlæggelser af kræftpatienter

/ Alexander Fuglkjær
AIASH24Lymfom Play the Video 01:57
Ingrid Glimelius

Zilovertamab Vedotin in Mantle Cell Lymphoma: Promising Results from ASH 2024

/ Ingrid Glimelius
ASH24Lymfom Play the Video 01:46
Ingrid Glimelius

High Mortality Rate for Patients with Mantle Cell Lymphoma with a Second Primary Malignancy

/ Ingrid Glimelius
ASH24Lymfom Play the Video 03:27
Timothy Fenske

The Majority of Patients with Mantle Cell Lymphoma Probably Don’t Need Auto-Transplant in the Current Treatment Era

/ Timothy S. Fenske
ASH24Lymfom Play the Video 05:17
Mats Jerkeman

There Is Definitely A Need for Novel Treatments for Elderly Patients with Mantle Cell Lymphoma

/ Mats Jerkeman
ASH24Lymfom Play the Video 03:13
Martin Dreyling

ECHO Trial Highlights Acalabrutinib’s Promise in Mantle Cell Lymphoma Treatment

/ Martin Dreyling
ASH24Lymfom Play the Video 03:48

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

/ BestPractice Nordic
EHA24Myelomatose

EHA 2024: One of the Most Important for Many Years

/ BestPractice Nordic
EHA24Lymfom

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
EHA24CLL
Back to top